Case Series of Pneumocystis Jirovecii Pneumonia in Post-Covid-19 Disease

Ayub, Maaha; Zubairi, Mustafa Bin Ali; Zubairi, Ali Bin Sarwar

doi:10.1016/j.chest.2021.07.404

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The search conducted in the databases resulted in 1282 articles, of which 33 met the inclusion criteria 23 – 55 ( Figure 1 ). The reviewed articles are summarized in Table 1 .…”

Section: Resultsmentioning

confidence: 99%

Fungal infections in patients after recovering from COVID-19: a systematic review

Ulloque-Badaracco,

Copaja-Corzo,

Hernandez-Bustamante

et al. 2024

Therapeutic Advances in Infection

View full text Add to dashboard Cite

Background and aims: The presence of fungal infections has been described in patients after recovering from COVID-19. This study aims to conduct a systematic review of studies that reported fungal infections ( Mucor spp., Pneumocystis jirovecii, or Aspergillus spp.) in adults after recovering from COVID-19. Methods: We performed a systematic review through PubMed, Web of Science, OVID-Medline, Embase, and Scopus. The study selection process was performed independently and by at least two authors. We performed a risk of bias assessment using the Newcastle–Ottawa Scale for cohort and case–control studies, and the Joanna Briggs Institute’s Checklists for Case Series and Case Reports. Results: The systematic search found 33 studies meeting all inclusion criteria. There was a total population of 774 participants, ranging from 21 to 87 years. From them, 746 developed a fungal infection. In 19 studies, Mucor spp. was reported as the main mycosis. In 10 studies, P. jirovecii was reported as the main mycosis. In seven studies, Aspergillus spp. was reported as the main mycosis. Regarding the quality assessment, 12 studies were classified as low risk of bias and the remaining studies as high risk of bias. Conclusion: Patients’ clinical presentation and prognosis after recovering from COVID-19 with fungal infection differ from those reported patients with acute COVID-19 infection and those without COVID-19 infection.

show abstract

“…The search conducted in the databases resulted in 1282 articles, of which 33 met the inclusion criteria 23 – 55 ( Figure 1 ). The reviewed articles are summarized in Table 1 .…”

Section: Resultsmentioning

confidence: 99%

Fungal infections in patients after recovering from COVID-19: a systematic review

Ulloque-Badaracco,

Copaja-Corzo,

Hernandez-Bustamante

et al. 2024

Therapeutic Advances in Infection

View full text Add to dashboard Cite

show abstract

Pneumocystis jiroveciiInfections Among COVID-19 Patients: A Case Series and Literature Review

Amstutz

Bahr

Snyder

et al. 2023

Open Forum Infectious Diseases

View full text Add to dashboard Cite

Pneumocystis jirovecii pneumonia (PCP) is a serious, emerging complication of coronavirus disease 2019 (COVID-19). We describe six new cases of PCP/COVID-19 co-infection and performed a systematic review of published cases. Among our cases (n=6) and those in the literature (n=69) with available data, median age was 59 [IQR: 44-77, n=38] years, 72% (47/65) were male, and the mortality rate was 30.9% (21/68). Long-term corticosteroid use was noted in 45.1% (23/51), advanced human immunodeficiency virus (HIV) infection (defined as a CD4 count less than 200 cells per microliter (cells/mm 3 )) in 17.6% (9/51), and antineoplastic chemotherapy in 13.7% (7/51); consistent with known PCP risk factors. Notably, 56.7% (38/47) had verifiable risk factors for PCP (high-dose corticosteroids, immunosuppressive therapy, and HIV infection) prior to COVID-19 infection. A median absolute lymphocyte count of 0.61 x 103 cells/mm 3 [0.28-0.92, n=23] and a CD4 count 66 cells/mm3 [33-291.5, n=20] were also discovered among the study population. These findings suggest a need for greater attention to PCP risk factors among COVID-19 patients and consideration of PCP prophylaxis in these high-risk populations.

show abstract

Case Series of Pneumocystis Jirovecii Pneumonia in Post-Covid-19 Disease

Cited by 2 publications

References 0 publications

Fungal infections in patients after recovering from COVID-19: a systematic review

Fungal infections in patients after recovering from COVID-19: a systematic review

Pneumocystis jiroveciiInfections Among COVID-19 Patients: A Case Series and Literature Review

Contact Info

Product

Resources

About